Covance Opens Offices in Seoul, Mumbai

Thursday, December 17, 2009 07:42 AM

Covance recently opened new clinical development offices in Seoul, South Korea, and Mumbai, India, building on the contract research organization’s (CRO) two-decade history in the Asia-Pacific region.

The new and expanded offices will help the CRO meet growing demand for clinical development services in Asia-Pacific. The Seoul office will increase patient access in the region and support Covance’s field-based clinical research associates throughout Asia-Pacific, while the Mumbai office will serve as the CRO’s main support hub for the Indian sub-continent.

The company also expanded its offices in Tokyo, Japan, and Hong Kong, China, to increase service capacity in these countries. The Tokyo office will provide additional room for both clinical development and central laboratory services in the Japanese clinical trial market.

"Our new Asia-Pacific offices support our global expansion strategy, which targets the most qualified investigators and appropriate patient populations in a region that is increasingly important to clinical trials," said Nick Wright, vice president and general manager, clinical development services Asia-Pacific, Covance. "These offices will help us increase our clients' phase II/III clinical trial productivity by providing additional capacity to execute clinical studies with a full range of services."

The year 2009 was a big year for growth in emerging markets at Covance, which opened nine new offices in Asia Pacific, Latin America and Eastern Europe.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs